CDKN2A and MC1R analysis in amelanotic and pigmented melanoma

Melanoma Research

Volumn 19, Issue 3, 2009, Pages 142-145

  Ghiorzo, Paola ^a   Pastorino, Lorenza ^a   Pizzichetta, Maria A ^c   Bono, Riccardo ^d   Queirolo, Paola ^b   Talamini, Renato ^c   Annessi, Giorgio ^d   Bruno, William ^a   Nasti, Sabina ^a   Gargiulo, Sara ^a   Battistuzzi, Linda ^a   Sini, Maria C ^e   Palmieri, Giuseppe ^e   Scarrà, Giovanna Bianchi ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^e CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MELANOCORTIN 1 RECEPTOR;

AMELANOTIC MELANOMA; ARTICLE; CASE STUDY; CLINICAL ARTICLE; FAMILY; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; MALE; PENETRANCE; PHENOTYPE; PIGMENTATION; PRIORITY JOURNAL; ALTERNATIVE RNA SPLICING; GENETIC PREDISPOSITION; GENETICS; ITALY; MUTATION; PATHOLOGY; PEDIGREE; SKIN TUMOR;

ALTERNATIVE SPLICING; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ITALY; MALE; MELANOMA, AMELANOTIC; MUTATION; PEDIGREE; PENETRANCE; PIGMENTATION; RECEPTOR, MELANOCORTIN, TYPE 1; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 67849103685     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32832a1e18     Document Type: Article

References (19)

1. Menzies SW, Kreusch J, Byth K, Pizzichetta MA, Marghoob A, Braun R, et al. Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. Arch Dermatol 2008; 144:1120-1127.
2. Tadokoro T, Kobayashi N, Zmudzka BZ, Ito S, Wakamatsu K, Yamaguchi Y, et al. UV-induced DNA damage and melanin content in human skin differing in racial/ethnic origin. FASEB J 2003; 17:1177-1179.
3. Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 1999; 9:22-30.
4. Sarkar-Agrawal P, Vergilis I, Sharpless NE, DePinho RA, Rünger TM. Impaired processing of DNA photoproducts and ultraviolet hypermutability with loss of p16INK4a or p19ARF. J Natl Cancer Inst 2004; 96:1790-1793.
5. Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001; 117:294-300.
6. Rouzaud F, Kadekaro AL, Abdel-Malek ZA, Hearing VJ. MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res 2005; 571:133-152.
7. Pizzichetta MA, Talamini R, Stanganelli I, Puddu P, Bono R, Argenziano G, et al. Amelanotic/hypomelanotic melanoma: clinical and dermoscopic features. Br J Dermatol 2004; 150:1117-1124.
8. Ghiorzo P, Gargiulo S, Pastorino L, Cusano R, Bruno W, Gliori S, et al. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. Hum Mol Genet 2006; 15:2682-2689.
9. Harland M, Taylor CF, Chambers PA, Kukalizch K, Randerson-Moor JA, Gruis NA, et al. A mutation hotspot at the p14ARF splice site. Oncogene 2005; 24:4604-4608.
10. Mistry SH, Taylor C, Randerson-Moor JA, Harland M, Turner F, Barrett JH, et al. Prevalence of 9p21 deletions in UK melanoma families. Genes Chromosomes Cancer 2005; 44:292-300.
11. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006; 66 :9818-9828.
12. Beaumont KA, Shekar SN, Newton RA, James MR, Stow JL, Duffy DL, et al. Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. Hum Mol Genet 2007; 16:2249-2260.
13. Hauser JE, Kadekaro AL, Kavanagh RJ, Wakamatsu K, Terzieva S, Schwemberger S, et al. Melanin content and MC1R function independently affect UVR-induced DNA damage in cultured human melanocytes. Pigment Cell Res 2006; 19:303-314.
14. Ringholm A, Klovins J, Rudzish R, Phillips S, Rees JL, Schiöth HB, et al. Pharmacological characterization of loss of function mutations of the human melanocortin 1 receptor that are associated with red hair. J Invest Dermatol 2004; 123:917-923.
15. Packer LM, Pavey SJ, Boyle GM, Stark MS, Ayub AL, Rizos H, et al. Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF. Int J Cancer 2007; 121:784-790.
16. Zhang W, Tsan R, Nam DH, Lu W, Fidler IJ. Loss of adhesion in the circulation converts amelanotic metastatic melanoma cells to melanotic by inhibition of AKT. Neoplasia 2006; 8:543-550.
17. Cohen-Solal KA, Crespo-Carbone SM, Namkoong J, Mackason KR, Roberts KG, Reuhl KR, et al. Progressive appearance of pigmentation in amelanotic melanoma lesions. Pigment Cell Res 2002; 15:282-289.
18. Latendresse JR, Muskhelishvili L, Warbritton A, Tolleson WH. Two cases of uveal amelanotic melanoma in transgenic Tyr-HRAS + Ink4a/Arf heterozygous mice. Toxicol Pathol 2007; 35:827-832.
19. Sini MC, Manca A, Cossu A, Budroni M, Botti G, Ascierto PA, et al. Molecular alterations at chromosome 9p21 in melanocytic nevi and melanoma. Br J Dermatol 2008; 158:243-250.